MarkWide Research - Global Market Intelligence Platform
Report Details
Historical Year
2020-2024
Base Year
2025
Forecast Period
2026-2036
Published Date
May 2026
No. of Pages
247 Pages
Delivery Format
PDF + Excel
Home›Industries›Healthcare›Gastroenterology›Gastric Cancer Market

Gastric Cancer Market Size, Share, and Industry Trends Forecast 2026-2036

The Gastric Cancer Market valued at $4.8 Billion in 2026 is projected to expand to $10.17 Billion by 2035, advancing at a 8.70% CAGR over the analysis window. Oncology clinics in Japan and South Korea are expanding molecular profiling capabilities for HER2-positive and CLDN18.2-expressing tumors. The FDA's accelerated approval pathway and EMA's adaptive licensing frameworks are compressing development timelines for novel biologics. Demand concentrates in East Asian metropolitan hospital networks where Helicobacter pylori screening programs have matured into precision treatment pipelines.

Gastric Cancer Market Analysis

Market Dynamics

Oncology-trained pathologists and biomarker specialists is rotating toward immuno-oncology and antibody-drug conjugate programs, tightening labor availability for conventional chemotherapy oversight. Bristol Myers Squibb dominates checkpoint inhibitor development for MSI-high gastric tumors across North American and European trial networks. Merck & Co., Inc. anchors pembrolizumab-based combinations through its extensive investigator-sponsored research program in Asia-Pacific academic centers. Daiichi Sankyo differentiates through HER2-directed ADC technology and emerging CLDN18.2-targeted constructs in Japanese and Chinese regulatory filings.

Technical and Segment Structure

Gastric cancer encompasses malignant neoplasms arising from the gastric mucosa, classified histologically as adenocarcinoma (intestinal and diffuse Lauren types), with staging per AJCC TNM criteria incorporating tumor penetration, nodal involvement, and metastatic spread to guide multimodal intervention. Immunotherapy now occupies the fastest-expanding margin pool as PD-1/PD-L1 inhibitors displace second-line chemotherapy across major markets, while targeted therapy sustains premium positioning in HER2-amplified and FGFR2-altered subsets. Intravenous delivery controls the revenue base for hospital-administered biologics, though oral formulations in targeted therapy are gaining share in ambulatory settings where patient throughput pressures mount.

Regulatory Environment

The FDA's Project Orbis and EMA's PRIority MEdicines scheme are reshaping simultaneous submission patterns for gastric cancer therapeutics across the United States and European Union. Japan's PMDA Sakigake designation and China's NMPA breakthrough therapy pathway add parallel acceleration channels that compress Phase I-to-approval timelines for novel mechanisms. Stakeholders must monitor biomarker-defined subgroup dynamics as regulatory bodies condition approvals on companion diagnostic co-development, forcing portfolio decisions between broad cytotoxic plays and narrowly targeted precision assets.

Gastric Cancer Market Size and Forecast

Market Dynamics

Precision biomarker stratification is compressing addressable populations for broad-spectrum chemotherapy while expanding premium segments for targeted biologics, fundamentally restructuring commercialization economics across oncology portfolios.

Growth Catalysts

  • Japan's PMDA Sakigake designation:This accelerated pathway compresses Phase I-to-approval timelines for novel CLDN18.2-targeted constructs, incentivizing sponsors to prioritize Japanese regulatory filings.
  • Companion diagnostic co-development mandates:FDA and EMA conditioning of approvals on parallel diagnostic validation is standardizing HER2 and PD-L1 testing infrastructure in hospital networks.
  • East Asian metropolitan hospital concentration:Seoul and Tokyo oncology centers are consolidating molecular profiling capabilities, creating dedicated referral pipelines for biomarker-selected trials.

Market Restraints

  • Platinum-based chemotherapy input cost volatility:Manufacturing concentration for cisplatin and oxaliplatin active pharmaceutical ingredients in Chinese and Indian suppliers exposes formulators to supply interruptions.
  • Biomarker testing infrastructure gaps:Community oncology practices outside major Japanese and South Korean cities lack in-house next-generation sequencing capacity, fragmenting patient identification.
  • Checkpoint inhibitor substitution pressure:Pembrolizumab and nivolumab expansion across earlier treatment lines is narrowing commercial runway for second-line cytotoxic agents.

Strategic Opportunities

  • China's NMPA breakthrough therapy pathway:Domestic sponsors and multinational joint ventures can secure priority review for CLDN18.2-directed assets, compressing competitive entry timelines.
  • Ambulatory oral formulation expansion:Targeted therapy candidates with bioavailability profiles suitable for outpatient administration can capture patient throughput pressures in Japanese day-clinic networks.
  • Antibody-drug conjugate technology convergence:HER2-directed ADC platforms combining cytotoxic payloads with immunomodulatory linkers represent whitespace beyond trastuzumab deruxtecan's current positioning.

Industry Challenges

  • Oncology pathologist talent scarcity:Specialized labor for MSI-high and EBV-positive tumor classification is rotating toward immuno-oncology programs, constraining conventional histopathology throughput.
  • Companion diagnostic certification timelines:Parallel PMA and CE-IVD submissions for PD-L1 assays create regulatory synchronization complexity across US and EU filing strategies.
  • Legacy chemotherapy manufacturing reconfiguration:Contract manufacturers face asset-stranding risk as demand shifts from cytotoxic bulk production toward biologics fill-finish capacity.

Report Scope

MarkWide Research
AttributesDetails
Report TitleGastric Cancer Market
Market Size in 2026$4.8 Billion
Market Size in 2035$10.17 Billion
CAGR (2026 – 2036)8.7%
Historical Year2020-2024
Base Year2025
Forecast Period2026-2036
Segmentation
Product Type: Chemotherapy, Immunotherapy, Targeted Therapy, Radiotherapy
End User: Hospitals, Oncology Clinics, Research Institutes, Ambulatory Surgical Centers
Therapy Area: Surgery, Chemoradiotherapy, Palliative Care, Precision Medicine
Delivery Mode: Intravenous, Oral, Subcutaneous, Topical
Companies CoveredNovartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Others
Regions Covered
North America: US, Canada, Mexico
Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Indonesia, Malaysia, Kazakhstan, Taiwan, Vietnam, Thailand, Philippines, Singapore, Australia, New Zealand, Rest of Asia Pacific
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Middle East & Africa: Saudi Arabia, UAE, Qatar, South Africa, Israel, Kuwait, Oman, North Africa, West Africa, Rest of MEA

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Gastric Cancer Market Emerging Trajectories

Antibody-drug conjugate engineering is redefining therapeutic index expectations in solid tumor oncology, with payload diversification and linker optimization emerging as the primary vectors of clinical differentiation.

CLDN18.2-targeted ADC constructs are fragmenting the HER2-dominated targeted therapy landscape in gastric adenocarcinoma. Japanese and Chinese academic medical centers are prioritizing these assets in first-line combination trials. The technology is fragmenting traditional chemotherapy-backbone protocols by enabling biomarker-selected de-escalation strategies.

EMA's PRIority MEdicines scheme and FDA's Project Orbis are compressing multiregional submission timelines for novel mechanisms. Parallel scientific advice procedures are becoming standard for gastric cancer sponsors with Asia-Pacific development strategies. MSI-high and EBV-positive subpopulations are attracting disproportionate regulatory attention, conditioning approval pathways on prospective biomarker enrichment.

Japanese day-clinic networks are unbundling infusion center services from inpatient oncology departments. Patients with stable disease on maintenance immunotherapy are migrating to ambulatory settings with lower reimbursement intensity. South Korea's National Health Insurance Service is piloting episode-based payment models for adjuvant therapy sequences, accelerating this channel shift in Seoul metropolitan clusters.

Gastric Cancer Market Segmentation

Gastric Cancer Market Segment

Segmentation in gastric cancer therapeutics reveals divergent margin economics across modalities. Biologics command premium positioning in biomarker-selected subsets while conventional cytotoxics face volume pressure from checkpoint inhibitor displacement.

Product Type:

Immunotherapy and targeted biologics capture the deepest margin pools as precision biomarker stratification compresses addressable populations for broad-spectrum agents.

  • Immunotherapy:PD-1/PD-L1 checkpoint inhibitors displace second-line chemotherapy across major markets. Demand concentrates in East Asian metropolitan hospital networks where MSI-high screening infrastructure enables patient identification for pembrolizumab and nivolumab regimens.
  • Targeted Therapy:HER2-directed antibody-drug conjugates and emerging CLDN18.2-targeted constructs redefine therapeutic index expectations. Japanese and Chinese regulatory filings prioritize these assets, with Daiichi Sankyo leading HER2-ADC development and domestic sponsors advancing CLDN18.2 programs through NMPA breakthrough therapy pathways.
  • Chemotherapy:Platinum-fluoropyrimidine backbones remain foundational in first-line settings despite margin erosion.
  • Radiotherapy:Adjuvant and neoadjuvant applications persist in localized disease staging protocols.

The dominant share belongs to immunotherapy, while targeted therapy is closing the gap fastest as ADC technology matures.

End User:

Patient throughput pressures and reimbursement intensity vary sharply across settings, with metropolitan academic centers capturing biomarker-selected trial volume.

  • Hospitals:Inpatient oncology departments administer complex combination regimens requiring toxicity monitoring. Seoul and Tokyo tertiary centers consolidate molecular profiling capabilities, creating dedicated referral pipelines for biomarker-enriched protocols.
  • Oncology Clinics:Specialized units in Japan and South Korea rotate pathology talent toward immuno-oncology programs. These facilities face labor scarcity for conventional histopathology as MSI-high and EBV-positive classification demands intensify.
  • Ambulatory Surgical Centers:Day-clinic networks unbundle infusion services from inpatient departments.
  • Research Institutes:Academic medical centers anchor investigator-sponsored combination trials.

Hospitals retain the largest patient volume, though oncology clinics are expanding their share fastest as precision medicine centralizes in specialized settings.

Therapy Area:

Commercial runway length depends on treatment-line positioning, with earlier-stage interventions offering extended revenue capture.

  • Precision Medicine:Biomarker-directed sequencing enables de-escalation strategies and targeted agent selection. Companion diagnostic co-development mandates from FDA and EMA standardize HER2 and PD-L1 testing infrastructure, conditioning approvals on parallel diagnostic validation.
  • Chemoradiotherapy:Neoadjuvant protocols preceding surgical resection maintain established reimbursement pathways.
  • Surgery:Curative-intent resection with D2 lymphadenectomy remains standard in East Asian practice patterns.
  • Palliative Care:End-stage symptom management occupies distinct reimbursement categories with lower intensity.

Precision medicine commands the steepest expansion trajectory, while chemoradiotherapy holds stable share in perioperative protocols.

Delivery Mode:

Administration setting requirements shape competitive dynamics between hospital-dependent and ambulatory-capable formats.

  • Intravenous:Hospital-administered biologics control the revenue base, with infusion center capacity constraints limiting patient throughput. Japanese day-clinic networks are piloting unbundled services for stable maintenance immunotherapy patients.
  • Oral:Targeted therapy formulations with suitable bioavailability profiles gain traction in outpatient settings. South Korea's National Health Insurance Service episode-based payment pilots accelerate this channel shift in Seoul metropolitan clusters.
  • Subcutaneous:Self-administration potential reduces facility dependency for selected agents.
  • Topical:Limited application in gastric malignancies given anatomical access constraints.

Intravenous delivery maintains dominant position, though oral formulations are gaining share fastest as ambulatory pressures mount.

Gastric Cancer Market Segmentation

Need this report tailored to your region?

Request specific countries, segments, or companies — tailored to your requirements.

Regional Outlook

Japan and South Korea consume gastric cancer therapeutics through precision biomarker pipelines that differ sharply from the chemotherapy-centric protocols still dominant in Western European and North American markets. East Asian metropolitan hospital networks have matured Helicobacter pylori screening into molecular profiling referral systems, while Western markets lag in companion diagnostic infrastructure deployment.

Japan

PMDA Sakigake designation accelerates CLDN18.2-targeted construct development, compressing Phase I-to-approval timelines for novel biologics. Tokyo and Osaka tertiary centers consolidate molecular profiling capabilities, creating dedicated referral pipelines for biomarker-enriched protocols that fragment traditional chemotherapy-backbone treatment patterns.

South Korea

Seoul metropolitan oncology clusters anchor investigator-sponsored combination trials for HER2-directed antibody-drug conjugates. The National Health Insurance Service pilots episode-based payment models for adjuvant therapy sequences, accelerating patient migration from inpatient departments to ambulatory day-clinic networks.

United States

FDA Project Orbis enables simultaneous submission patterns with European and Asian regulators, reshaping multiregional development timelines for gastric cancer therapeutics. Major academic medical centers in Boston and Houston standardize MSI-high and PD-L1 testing infrastructure, though community oncology practices outside these clusters face biomarker identification gaps.

China

NMPA breakthrough therapy pathways compress competitive entry timelines for domestic sponsors advancing CLDN18.2-directed assets. Shanghai and Beijing hospital networks expand molecular profiling capacity, yet manufacturing concentration for platinum-based chemotherapy active pharmaceutical ingredients exposes formulators to supply interruption risks.

Germany

EMA PRIority MEdicines scheme and parallel scientific advice procedures attract sponsors with Asia-Pacific development strategies. Heidelberg and Munich academic centers participate in multinational biomarker-enriched trials, though reimbursement intensity for checkpoint inhibitors varies across statutory health insurance regional associations.

Gastric Cancer Market Vendor Landscape

A small set of integrated leaders sits above a broader specialist tier, with multinational pharmaceutical conglomerates controlling checkpoint inhibitor and antibody-drug conjugate development against a backdrop of regional biotech ventures. The upper tier compresses clinical trial timelines through established investigator networks, while mid-cap specialists concentrate on single-asset biomarker-selected indications. Three archetypes dominate: integrated oncology majors with global trial infrastructure, Japanese and Chinese biotechs with regulatory pathway expertise, and contract research organizations with biomarker co-development capabilities. Competitive moves center on companion diagnostic partnerships and adaptive licensing submissions across FDA, EMA, and PMDA jurisdictions.

Within the integrated oncology tier, Bristol Myers Squibb and Merck & Co., Inc. anchor checkpoint inhibitor development through extensive academic center networks, while Daiichi Sankyo occupies a distinctive position in HER2-directed antibody-drug conjugate technology. These three entities exemplify divergent strategic postures: one leverages North American and European trial density, another anchors pembrolizumab-based combinations through Asia-Pacific investigator-sponsored research, and the third differentiates through emerging CLDN18.2-targeted constructs in Japanese and Chinese regulatory filings.

Leading Market Players
Novartis AG
Pfizer, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
AstraZeneca
Daiichi Sankyo
Teva Pharmaceutical Industries Ltd.
Others
Please note: The company list above is for reference and is subject to change. The final study will cover 15–20 leading companies in this market, and the final selection can be tailored to the client's specific requirements.

Supply Flow & Price Mechanics

Checkpoint inhibitor substitution for platinum-fluoropyrimidine backbones simultaneously relocates manufacturing value toward biologics fill-finish facilities in Japan and South Korea while compressing pricing power for generic cytotoxic suppliers in China and India.

Pricing Analysis

Contract structures in gastric cancer therapeutics favor long-term offtake agreements for checkpoint inhibitors and antibody-drug conjugates, with spot purchasing limited to platinum-based chemotherapy inputs. Price differentiation rests on biomarker selection criteria and companion diagnostic bundling, with HER2-directed ADCs commanding premium positioning against commoditized cytotoxics. Cost compression in second-line chemotherapy intensifies as pembrolizumab and nivolumab displace earlier protocols. Community oncology practices exhibit highest price sensitivity due to reimbursement compression, while metropolitan academic centers prioritize clinical efficacy over acquisition cost.

Supply Chain Analysis

Inventory strategy across gastric cancer therapeutics favors just-in-time delivery for temperature-sensitive biologics, with strategic stockpiling concentrated among platinum API formulators hedging against Chinese and Indian supply interruptions. Manufacturing concentration for cisplatin and oxaliplatin active pharmaceutical ingredients in China and India creates single-source vulnerability for chemotherapy backbones. Distribution runs through hospital-administered channels for intravenous biologics, with Japanese day-clinic networks piloting unbundled outpatient models for maintenance immunotherapy.

Gastric Cancer Market SWOT Analysis

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Analyst Recommendations

The gastric cancer therapeutics sector sits at an inflection where CLDN18.2-targeted ADC technology and PMDA Sakigake acceleration are fragmenting established treatment hierarchies.

For Market Incumbents: Compound defensive positioning through backward integration into companion diagnostic co-development and captive biologics manufacturing capacity in Osaka and Seoul metropolitan clusters. Prioritize regulatory synchronization across FDA Project Orbis and EMA PRIority MEdicines schemes to compress competitive entry timelines for emerging CLDN18.2-directed constructs. For New Entrants and Emerging Players: Biomarker testing infrastructure gaps in community oncology practices outside major Japanese and South Korean cities present service-layer entry points. Target ambulatory oral formulation development for Japanese day-clinic networks, leveraging South Korea's National Health Insurance Service episode-based payment pilots as the primary go-to-market pathway. For Investors and Strategic Acquirers: The market sits at a technology-transition phase that favors antibody-drug conjugate platform specialists with regulatory pathway expertise in Japan and China. Long-term viability hinges on biomarker-enriched trial infrastructure and parallel diagnostic validation capabilities. Watch FDA conditioning of approvals on companion diagnostic co-development as the signal for portfolio consolidation timing.
Strategic Initiative Industry Significance
Companion Diagnostic Co-Development FDA and EMA mandates condition pembrolizumab approvals on parallel PD-L1 assay validation.
Antibody-Drug Conjugate Platform Expansion HER2-directed and CLDN18.2-targeted constructs redefine therapeutic index expectations in gastric adenocarcinoma.
Regulatory Pathway Synchronization PMDA Sakigake and NMPA breakthrough therapy designations compress Phase I-to-approval timelines for novel biologics.
Ambulatory Infusion Network Unbundling Japanese day-clinic networks capture maintenance immunotherapy volume from inpatient oncology departments.
Biomarker Testing Infrastructure Deployment MSI-high and EBV-positive classification capacity concentrates in Seoul and Tokyo tertiary centers.

Methodological Framework

A spread of perspectives from oncology development executives, regulatory affairs leads, hospital procurement managers, and payer access specialists converged on the working assumptions driving this analysis. Primary fieldwork combined structured interviews with secondary validation against FDA filings, EMA submissions, ClinicalTrials.gov records, and formulary databases. Bottom-up patient-flow modeling and top-down revenue triangulation anchored market sizing across the projection horizon.

Segmentation dimensions modeled include treatment line positioning, administration route, biomarker-selected patient population, and regional regulatory cluster. CAGRs were derived from therapy-area growth trajectories and modality displacement patterns. Forecast inputs incorporated checkpoint inhibitor expansion timelines, ADC technology maturation curves, and companion diagnostic adoption rates.

Underlying assumptions cover regulatory approval continuity and biomarker testing infrastructure deployment, with deviation risk concentrated in platinum API supply interruptions and checkpoint inhibitor substitution velocity. Revision becomes warranted when CLDN18.2-directed asset approval timelines or companion diagnostic certification delays cross material thresholds.

Need Custom Data?

Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.

1,000+

Global Clients

150+

Countries Covered

65,000+

Reports Available

Frequently Asked Questions

Why Work With MWR

Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.

Ready to access intelligence that moves business?

Browse Reports →

Trusted by Global Leaders

From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.

Multi-Language Support

Research available in French, German, Spanish, Chinese, and more.

ISO & IAF Certified

Globally aligned quality standards ensuring methodological discipline and data integrity.

Competitive Relevance

Free inclusion of 3–4 additional companies of your choice in every report.

Customized Insights

Tailored intelligence for market entry, niche expansion, or competitive benchmarking.

Post-Sale Assistance

Dedicated coordination to help interpret findings and address queries post-delivery.

Cutting-Edge Methods

Structured data collection, advanced analytics, and expert validation for reliable forecasts.

Value for Investment

Credible, structured intelligence at a cost that makes strategic sense.

What Our Clients Say

"

My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.

Accenture

"

We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.

Mondelez

Director of Global Consumer Insights

"

For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.

BCG

"

We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.

Siemens

Head of Industrial Digitalization

"

During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.

KPMG

Advisory Partner

"

We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.

Deloitte

Lead Consultant, Sustainability Services

"

For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.

Samsung

"

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.

3M

"

I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.

VITO

Buy Now